Redhill Biopharma RDHL

NAS: RDHL | ISIN: US7574681034 26/04/2024

0,428 USD (+2,84%)

(+2,84%) 26/04/2024

Grafiek Redhill Biopharma

Grafiek Redhill Biopharma

1 dag1d 2,84%
1 week1w -3,25%
1 maand1m -16,42%
3 maanden3m -33,48%
6 maanden6m -9,49%
1 jaar1j -81,23%
5 jaar5j -94,58%

Redhill Biopharma in het nieuws

Toon enkel gratis nieuws

24 april 2024 · RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study · Persbericht

8 april 2024 · RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights · Persbericht

2 april 2024 · RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price · Persbericht

11 maart 2024 · RedHill Announces New USPTO Patent Covering Talicia® Through 2034 · Persbericht

5 maart 2024 · RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs · Persbericht

20 februari 2024 · RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication · Persbericht

26 januari 2024 · RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering · Persbericht

25 januari 2024 · RedHill Biopharma Announces $8 Million Registered Direct Offering · Persbericht

25 januari 2024 · RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 · Persbericht

20 december 2023 · RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola · Persbericht

Profiel Redhill Biopharma

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

CEO: Dror Ben-Asher

Werknemers: 150

Aandelen Redhill Biopharma

Beurswaarde: 377,38 duizend USD

Effecten: 881,74 duizend

Beta: -0,25

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe